Abstract. The basal promoter activity of the human AT 1 receptor gene was characterized using a human hepatoma cell line with a considerably high expression of AT 1 , PLC-PRF-5. Four cis-acting, positively regulating elements termed AT 1 PRE1 (-113 to -102 bp), AT 1 PRE2 (-49 to -43 bp), AT 1 PRE3 (-5 to -2 bp) and AT 1 PRE4 (+44 to +50 bp) were identified. AT 1 PRE2 contained a GC-box-like sequence and bound to Sp1. AT 1 PRE1 contained two tandem GC-boxes and was bound to several nuclear proteins in addition to Sp1. Nuclear proteins that were bound sequence-specifically to AT 1 PRE1, AT 1 PRE2 and AT 1 PRE4 were found in both PLC-PRF-5 cells and 8505C cells, while those bound to AT 1 PRE3 were not found in 8505C cells, which showed no expression of AT 1 and almost no promoter activity for the AT 1 gene. Significant promoter activity was still observed even when AT 1 PRE1, AT 1 PRE2 and AT 1 PRE4 were all mutated. Mutagenesis of AT 1 PRE3, however, substantially inactivated promoter activity. AT 1 PRE1, AT 1 PRE2 and AT 1 PRE4 synergistically enhanced AT 1 gene transcription promoted by AT 1 PRE3. These results suggested that AT 1 PRE3 is responsible for the tissue-specific expression of the human AT 1 gene, and that AT 1 PRE1, AT 1 PRE2 and AT 1 PRE4 function as a general enhancer in liver-derived cells. THE renin-angiotensin system plays an important role in the regulation of blood pressure, fluid volume and electrolyte homeostasis. Angiotensin II, the effector peptide in this system, not only exerts numerous physiological responses but also causes various cardiovascular diseases through its specific membrane-bound receptors. Pharmacological analyses by the non-peptide angiotensin II antagonists have revealed the existence of two distinct subtypes for angiotensin II receptors, designated type 1 (AT 1 ) and type 2 (AT 2 ). Most of the above known functions of angiotensin II are mediated by the AT 1 receptor. The primary structures of the AT 1 and the AT 2 receptor were determined in 1991 [1, 2] and 1993 [3] [4] [5] , respectively, by their cDNA cloning. The genomic structures of the AT 1 and the AT 2 receptor gene have also been reported [9] [10] [11] [12] [13] [14] [15] [16] [17] , with rapid progression of research on the intracellular signal transduction mechanism [18] [19] [20] .
THE renin-angiotensin system plays an important role in the regulation of blood pressure, fluid volume and electrolyte homeostasis. Angiotensin II, the effector peptide in this system, not only exerts numerous physiological responses but also causes various cardiovascular diseases through its specific membrane-bound receptors. Pharmacological analyses by the non-peptide angiotensin II antagonists have revealed the existence of two distinct subtypes for angiotensin II receptors, designated type 1 (AT 1 ) and type 2 (AT 2 ). Most of the above known functions of angiotensin II are mediated by the AT 1 receptor. The primary structures of the AT 1 and the AT 2 receptor were determined in 1991 [1, 2] and 1993 [3] [4] [5] , respectively, by their cDNA cloning. The genomic structures of the AT 1 and the AT 2 receptor gene have also been reported [9] [10] [11] [12] [13] [14] [15] [16] [17] , with rapid progression of research on the intracellular signal transduction mechanism [18] [19] [20] .
Further analyses of cDNA clones encoding the AT 1 receptor have revealed the existence of two subtypes for the AT 1 receptor, termed AT 1a and AT 1b [6] [7] [8] , in rodents. These AT 1 receptor isoforms are encoded by distinct genes and their expression is regulated separately [6] [7] [8] [21] [22] [23] . In contrast, only a single AT 1 subtype has been reported in human. Although human AT 1 receptor is expressed abundantly in adrenal cortex, vasculature, kidney and liver, there are few reports about the basic mechanism of tissue-specific transcription of the human AT 1 gene.
In the present study, basal promoter activity was analyzed for the human AT 1 gene, which we cloned previously [13] . The cis-acting elements responsible for tissue-specific expression of the AT 1 gene were clarified using a human liver-derived cell line, PLC-PRF-5 cells, which express a considerable amount of AT 1 receptor [25] .
Materials and Methods

Cell culture
A human hepatocellular carcinoma cell line, PLC-PRF-5 and a human thyroid carcinoma cell line, 8505C, were obtained from JCRB (Japanese Collection of Research Bioresources) Cell Bank (Tokyo, Japan). PLC-PRF-5 cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS), 100 mU/ml of penicillin and 100 mU/ml of streptomycin. 8505C cells were similarly maintained except for the use of modified Eagle's medium (MEM) instead of DMEM.
Plasmid construction
A 5 kbp BamH I fragment (HATR1GB) containing the 5'-upstream region of the AT 1 gene was isolated from a human peripheral lymphocyte genomic library [13] . A Hinc II-Sac II fragment from HATR1GB, which included 3418 bp of the 5'-flanking region and 79 bp of the first exon of the human AT 1 receptor gene, was subcloned into the promoterless, enhancerless firefly luciferase reporter vector, PGV-B (TOYO INK, Tokyo, Japan), at the Nhe I site by blunt end-ligation in both ordered and reverse orientations. The resultant plasmids were designated phAT 1 (-3418/+79)Luc and phAT 1 (+79/-3418)Luc. The mutants with sequential deletions of the 5'-flanking region were constructed from phAT 1 (-3418/+79)Luc using its restriction endonuclease sites of Bgl II (-1770), Rsa 1 (-265) and Sma I (-113), and by exonuclease III and mung bean nuclease-digestion. Deletion mutants of the proximal promoter region of the AT 1 gene were prepared by PCR using phAT 1 (-3418/+79)Luc as template. The 5'-region was amplified using a 20-base oligonucleotide corresponding to various portions of the 5'-proximal promoter region as the upstream (forward) primer and the downstream (reverse) primer, DS Bgl II primer, with a sequence of 5'-AAGATCTCGGCCCGGCAG AGCTGCT-3' corresponding to the exon 1 region from +61 to +79 bp with a 3'-adaptor (Bgl II). The 3'-region was amplified using the upstream primer, US primer, with a sequence of 5'-TCCCGAGAGGGAGGAGG TTG-3' (-150 to -131 bp), and the downstream primer (20 bases) corresponding to various portions of the 3'-region of exon 1 with a 3'-Bgl II adaptor. PCR products were then cloned into Mlu I-Bgl II sites of PGV-B. Introduction of mutations into the 5'-end region of the proximal promoter sequence was performed by PCR using the upstream primer containing a mutated sequence as described in the legends for Figure 4 , and the DS Bgl II primer. Introduction of mutations into the 3'-end region was carried out using the US primer and the downstream primer containing a mutated sequence as described in the legends for Figure 5 and 7. The PCR products were cloned into Mlu I (blunted)-Bgl II sites of PGV-B. Introduction of mutations into multiple regions of the proximal promoter sequence (-150 to +79, Fig. 9 ) was performed by applying sitedirected mutagenesis repeatedly to phAT 1 (-150/ +79)Luc using a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The sequences of the primers used for mutagenesis were 5'-GGGA GGGTCTCCCGGTTCGGTTCGGAGGAGGAGGG-3' (-126 to -92), 5'-CCAAGAAGCAGCAACGCAAC TCACTATAAATTCGG-3' (-62 to -28), 5'-AGTGA CAGGACGTCTGAGAAGGCGCGCCGC-3' (+31 to +60) and 5'-CCTCGCCAATGATTCCCTCGCCTGA CAGCC-3' (-19 to +11) (mutated sites are underlined), for M3, M4, M7 and M14, respectively (Fig. 9) . The resultant constructs with mutated promoter sequences were designated according to the mutated sites, such as phAT 1 M13(-150/+79)Luc. The firefly luciferase reporter vector with the high efficiency, pGL3 Vector (Promega), was used in some experiments, which are indicated in the text and figure legend. The validity of the structure of all the constructs was confirmed by sequencing.
Reporter assay
The cells cultured in 6-well plates (3 × 10 5 cells/well) were transfected with 1.5 µg/well of phAT 1 (-3418/ +79)Luc or equivalent molar amounts of the mutated constructs, and 20 ng/well of phRL-TK (a HSVthymidine kinase promoter-based Renilla luciferase vector, Promega) as the internal control, using 4 µl/ well of LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's instructions. The cells were further incubated for 24 h in culture media containing 10% FCS and then solubilized with 500 µl of lysis buffer (Promega). The activities of the reporter gene were determined by the Dual-Luciferase Reporter Assay System (Promega) as previously described [26] .
Nuclear extracts
Nuclear extracts were prepared as previously described [27, 28] . In brief, cultured cells were gently homogenized in 0.3 M sucrose/2% Tween-40 in buffer A [10 mM HEPES-KOH, pH 7.9, containing 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg/ml leupeptin, 2 µg/ml pepstatin A and 2 µg/ml antipain], and was centrifuged on 1.5 M sucrose/buffer A. The resulting nuclear pellet was lysed in 0.42 M NaCl/10% glycerol in buffer A and centrifuged. The supernatant was dialyzed and stored at -80°C in 20 mM HEPES-KOH, pH 7.9, 40 mM KCl, 0.1 mM EDTA, 20% glycerol, 1 mM DTT, 0.5 mM PMSF, 2 µg/ml leupeptin and 2 µg/ml pepstatin A. The protein concentration was determined by a BCA Protein Assay Reagent kit (Pierce, Rockford, IL).
Gel mobility shift assay
Gel mobility shift assay was performed as previously described [27] [28] [29] . Double-stranded oligonucleotides were prepared by annealing the synthesized singlestranded oligonucleotides and subsequent purification on a 13% native polyacrylamide gel. The gel-purified double-stranded oligonucleotides were labeled with [γ-32 P]ATP using T4 polynucleotide kinase. Unincorporated radiolabel was removed with CHROMA SPIN-10 columns (Clontech, Palo Alto, CA). The specific activity of the labeled probes was approximately 10,000 cpm/fmol. Nuclear extract (3-5 µg) was incubated for 60 min at 12°C with or without unlabeled competitor oligonucleotides in 12 µl of a reaction mixture containing 12 mM HEPES-KOH, pH 7.9, 50 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 1 mM EDTA, 0.5 mM PMSF, 50 µg/ml acetylated BSA, 12.5% glycerol, 1 µg poly (dI-dC), and labeled probe (50,000 cpm). DNAprotein complexes were separated on 5% native polyacrylamide gels. In experiments using anti-Sp1 antibody (sc-59, Santa Cruz Biotechnology Inc, CA), nuclear extracts were incubated in the same buffer containing 2 µl of antibody or normal rabbit IgG at 12°C for 2 h before being processed as described above. Dried gels were subjected to autoradiography using Kodak XAR5 film and an intensifying screen at -80°C.
DNase I protection analysis
DNase I protection analysis was performed as previously reported [27] with minor modifications. Briefly, phAT 1 (-164/+79)Luc was cut with Hind III at the 5'-end of the inserted AT 1 proximal promoter region, endlabeled with [γ-32 P]ATP using T4 polynucleotide kinase after treatment with alkaline phosphatase, and recut with Xba I at the 3'-end of the inserted promoter region. The probes (15,000 cpm) were incubated with nuclear extracts (25-30 µg) on ice for 60 min in a 30 µl reaction mixture containing 12 mM HEPES-KOH, pH 7.9, 50 mM KCl, 2.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM PMSF, 10% glycerol, 50 µg/ml acetylated BSA, 0.5 mM DTT, 1 µg poly (dI-dC), followed by the addition of 3 µl of a digesting solution containing 10 mM HEPES-KOH, pH 7.9, 33 mM CaCl 2 , and 0.05-1U DNase I (TAKARA, Tokyo, Japan). The incubation was then continued for 1-3 min on ice. The reaction was terminated by the addition of 100 µl of a stopping solution containing 10 mM Tris-HCl, pH 7.6, 0.3 M NaCl, 0.1% sodium dodecyl sulfate, 20 mM EDTA, 10 µg tRNA and 20 µg proteinase K. After incubation at 45°C for 60 min, the DNA was extracted with phenol/chloroform, precipitated with ethanol, and separated on a 6% polyacrylamide/8 M urea sequencing gel. To define the position of the protected region, G + A and C + T sequence ladders were prepared [30] .
Binding assay
Angiotensin II-binding assay was performed using monoiodinated [Sar 1 , Ile 8 ]-angiotensin II ( 125 I-[Sar 1 , Ile 8 ]-angiotensin II, specific activity of 77.7-81.0 kBq/ pmol) as previously described [31, 32] .
Statistical analysis
The results were expressed as the mean ± SD. Oneway ANOVA followed by Scheffe's test was used for multigroup comparisons. P<0.05 was considered as statistically significant.
Results
Basal promoter activity of the 5'-flanking region of the human AT 1 gene
To analyze the promoter activity of the 5'-flanking region of the human AT 1 gene, we generated a chimeric construct in which 3418 bp of the 5'-upstream sequence from the transcriptional start site [13] and 79 bp of exon 1 of the human AT 1 gene were inserted immediately upstream to a promoterless firefly luciferase gene [phAT 1 (-3418/+79)Luc]. This reporter construct was transfected into the human liver carcinoma cell line, PLC-PRF-5 (PLC) and the human thyroid cancer cell line, 8505C, and the reporter activities were measured ( Fig. 1) . In PLC cells, phAT 1 (-3418/+79)Luc induced the reporter activity approximately 400 times compared with that of a promoterless vector, which did not contain the 5'-flanking sequence. The construct with the flanking sequence in reverse orientation, phAT 1 (+79/-3418)Luc, did not express luciferase activity in PLC cells. In 8505C cells, however, no significant promoter activity was detected. The promoter activity of phAT 1 (-3418/+79)Luc relative to that induced by a general promoter, the SV 40 promoter with its enhancer, was 48% in PLC cells (see legend to We then generated the reporter constructs, in which the 5'-flanking region of the AT 1 receptor gene was serially deleted, and the promoter activity was measured. In PLC cells, deletion from -3418 to -113 bp did not significantly affect the promoter activity, but deletion to -97 bp reduced the luciferase activity of phAT 1 (-3418/+79)Luc to 27% (Fig. 1) . We then sequentially deleted the proximal promoter region, and the reporter luciferase activities were assayed (Fig. 1) . Deletion from -67 to -42 bp, just before the putative TATA box, further reduced the reporter activity to 13%. Deletion to -25 bp, which removed the putative TATA box, markedly decreased the promoter activity to 0 to 1% of the activity of phAT 1 (-265/+79)Luc. These results suggested that a cis-acting, positively regulating element(s) (PRE), which functions in PLC cells, exists from -113 to -97 bp and from -67 bp to -42 bp. To determine whether a nuclear protein(s) binds specifically to these regions, a DNase I protection assay was performed. The protected regions from -118 to -100 bp ( Fig. 2A) and from -53 to -37 bp (Fig. 2B) were detected by the nuclear extracts from PLC cells.
Cis-acting, positively regulating elements (PRE) located in the -118 to -37 bp region of the human AT 1 gene promoter
The regions from -118 to -100 bp and from -53 to -37 bp detected by DNase I protection assay (Figs. 2A and 2B) contained the consensus sequence of a GC-box (-113 to -102 bp) and a GC-box-like sequence (-49 to -43 bp) (Fig. 3C) . We then performed a gel mobility shift assay using double-stranded oligonucleotides containing these regions as probes. The sequence from -113 to -102 bp consists of two GC-boxes located in tandem. Using a probe corresponding to the -123 to -93 bp region, four DNA-protein complexes were detected in the nuclear extract from PLC cells (Fig. 3A) . DNA-protein complexes were abolished by the inclusion of a wild type oligonucleotide (Fig. 3A, lane W) . The inclusion of an oligonucleotide with mutations within one GC-box (M1 or M2) abolished almost half of the DNA-protein complexes (Fig. 3A , lanes M1 and M2). On the other hand, the DNA-protein complexes were not abolished by the inclusion of an oligonucleotide with mutations in both GC-boxes (M3) (Fig. 3A , lane M3). The inclusion of an antibody for Sp1, which is one of the binding proteins specific for GC-boxes, supershifted about half of the four DNA-protein complexes (Fig. 3A , lanes Pre and Sp1). Using a doublestranded oligonucleotide corresponding to the -67 to -37 bp region as a probe, DNA-protein complexes similar to those observed using the -123 to -93 bp probe were detected in the nuclear extract from PLC cells (Fig. 3B ). These DNA-protein complexes were abolished by the inclusion of a wild type oligonucleotide (Fig. 3B , lane W), but not by an oligonucleotide containing mutations within the GC-box-like sequence (M4) (Fig. 3B, lane M4) . Almost all of the DNA- protein complexes were supershifted by the inclusion of an anti-Sp1 antibody (Fig. 3B , lanes Pre and Sp1).
To clarify the contribution of these GC-boxes and the GC-box-like sequence to promoter activity, we generated luciferase reporter vectors containing the -123 to +79 bp or -67 to +79 bp proximal promoter region, and introduced mutations within GC-boxes. The introduction of mutations into the two GC-boxes within the -113 to -102 bp region or the GC-box-like sequence within the -49 to -43 bp region decreased the promoter activity to 45-48% of that of the wild type (Fig. 4) . The extent of the changes in promoter activity by the introduction of mutations into the two GC-boxes and the GC-box-like sequence was consistent with that of the changes in reporter activity by deletion experiments shown in Figure 1 . Therefore, these GC-boxes and GC-box-like sequence were considered to be PREs detected by deletion experiments. We thus named the GC-boxes within the -113 to -102 bp region AT 1 PRE1, and the GC-box-like sequence within -49 to -43 bp AT 1 PRE2.
Basal promoter activity of the exon 1 region of the human AT 1 gene
Because more than 10% of the promoter activity of phAT 1 (-3418/+79)Luc still remained after deletion of the 5'-upstream region up to just before a putative TATA-box (Fig. 1) , we investigated the promoter effect of the exon 1 region of the AT 1 receptor gene. We generated mutants in which the exon 1 region of the AT 1 receptor gene was serially deleted from its 3'-end, and measured the luciferase activity in PLC cells. As shown in Figure 5A , deletion of the exon 1 region from +79 to +59 bp did not affect the luciferase activity, but deletion from +59 to +40 bp reduced the luciferase activity of phAT 1 (-150/+79)Luc in PLC cell to 37-40%. Further deletion of exon 1 from +40 to +5 bp did not affect the luciferase activity. These observations suggested that a PRE(s) resides between +40 and +59 bp in the exon 1 region. For further analysis of this PRE, constructs were generated in which mutations were sequentially introduced into this region. The luciferase activity of phAT 1 M6(-150/+63)Luc, which harbored mutations in the region from +43 to +46 bp, was 63 to 64% of that of the wild-type phAT 1 (-150/+63)Luc in PLC cells (Fig. 5B) . In addition, the activity of phAT 1 M7(-150/+63)Luc with mutations in the sequence from +47 to +50 bp was 41 to 45% of that of the wild type. The introduction of mutations into the +41 to +43 bp region (M5) or nucleotide positions (M8, 9 and 10) other than the sequence from +44 to +50 bp did not affect the promoter activity. These results suggested that the sequence from +44 to +50 bp plays a critical role in enhancement of transcriptional activity of the human AT 1 receptor gene.
A gel mobility shift assay was carried out using a 28-bp oligonucleotide as a probe corresponding to the sequence from +36 to +63 bp in the exon 1 region to determine whether there is a nuclear protein(s), which binds specifically to this region. A specific DNAprotein complex was observed using this probe, as well as the nuclear extracts from PLC and 8505C cells (Fig.  6 ). This DNA-protein complex was abolished by the inclusion of a 50-fold molar excess of an unlabeled wild-type oligonucleotide (Fig. 6, lane W) , an oligonucleotide mutated from +41 to +43 bp (M5), or an oligonucleotide mutated from +51 to +53 bp (M8). This DNA-protein complex was partially abolished by the inclusion of an oligonucleotide with mutations from +43 to +46 bp (M6) but never by an oligonucle- Luciferase reporter constructs with the wild-type sequences from -123 to +79 bp and from -67 to +79 bp, and those with sequences mutated as shown in M1, M3 and M4 were prepared by PCR, using the upstream primers with sequences shown in Figure 3C and the DS Bgl II primer as described under Materials and Methods. These constructs were transfected into PLC-PRF-5 cells. Luciferase activities were expressed as values relative to the activity induced by phAT 1 (-123/+79)Luc, which was set as 100%. Each bar represents the mean ± SD of three independent experiments. The GC-boxes (AT 1 PRE1) and GC-box-like sequence (AT 1 PRE2) are indicated.
otide with mutations from +47 to +50 bp (M7). These results suggested that the sequence from +44 to +50 bp of the human AT 1 receptor gene is an important region in the interaction with this nuclear protein. Taken together with the findings in the reporter assays shown in Figure 5B , the protein bound to the region from +44 to +50 bp of the human AT 1 receptor gene was suggested to be a transcriptional factor, which contributes to the transcriptional enhancement of the human AT 1 receptor gene. We named this PRE from +44 to +50 bp AT 1 PRE4. Since considerable promoter activity was still observed in phAT 1 (-150/+5)Luc, which was deleted up to +5 bp of exon 1 from its 3'-end, we examined the promoter activity of the region upstream from +5 bp of the human AT 1 receptor gene by the sequential introduction of mutations into the region from -7 to +6 bp. The introduction of mutations into the sequence A luciferase reporter construct with the wild-type sequence from -150 to +63 bp and the constructs with sequences mutated as shown in M5 to M10 (mutated sites are underlined) were generated by PCR using the US primer and the 24-base oligonucleotide downstream primers with sequences of M5 to M10 as described under Materials and Methods. Luciferase activities were expressed as values relative to the activity induced by phAT 1 (-150/+63)Luc, which was set as 100%. Fig. 6 . Gel mobility shift analysis of the cis-acting, positively regulating element, AT 1 PRE4 (+44 to +50 bp), in the AT 1 receptor gene promoter. The radiolabeled double-stranded oligonucleotide (+36 to +63 bp) (5'-CAGGACGTCTGGACCGGCGCGCCG CTAG -3') was incubated with 5 µg of nuclear extracts from PLC-PRF-5 (PLC) and 8505C cells with or without (-) a 10-or 50-fold molar excess of unlabeled wild-type (W) or mutated (M5 to M8) competitor oligonucleotides (double-stranded) as indicated, and analyzed as described under Materials and Methods. NE (-), incubation without nuclear extract. M5 to M8 were 28-base oligonucleotides (+36 to +63 bp) in which the sequence from +41 to +53 bp was mutated as shown in Figure 5 . The arrow indicates the DNA-protein complex formed by specific binding.
from -5 to -3 bp sites (M12 and M13) slightly decreased the luciferase activity (Fig. 7) . The luciferase activities induced by phAT 1 M14(-150/+18)Luc and phAT 1 M15(-150/+18)Luc, which harbored mutations in the sequence from -3 to -1 bp, were 5 to 12% compared with that by a wild type phAT 1 (-150/+18)Luc in PLC. On the other hand, the luciferase activities were not significantly affected by the introduction of mutations into the sequence at -7, -6 or -1 bp, or from +2 to +6 bp (M11 and M16-20). These findings demonstrated that the sequence from -5 to -2 bp of the human AT 1 gene promoter region functions as a PRE in PLC cells. We thus named the region from -5 to -2 bp AT 1 PRE3. We then tested whether this positive elements, AT 1 PRE3 and AT 1 PRE4, can regulate a heterologous promoter. The oligonucleotides corresponding to the sequence from -8 to +18 bp and that from +40 to +63 bp were subcloned downstream of the promoter of the pGL3-Promoter Vector, which has a promoter derived from SV 40, but no significant difference in the luciferase activity was observed (data not shown). This suggests that these cis-acting, positively regulating elements act only on the human AT 1 gene promoter.
To determine whether a specific protein(s) can bind to AT 1 PRE3, gel mobility shift assays were performed using a 26-bp oligonucleotide (-8 to +18 bp) as a probe. DNA-protein complexes formed with this probe in nuclear extracts from PLC cells (Fig. 8) . These shifted bands were completely abolished by the inclusion of a 100-fold molar excess of an unlabeled wildtype oligonucleotide. However, a trace of the DNAprotein complexes remained in the presence of the oligonucleotide M12 (mutated at -5 and -4 bp sites) or M13 (mutated at -4 and -3 bp sites), and were not abolished by the inclusion of the oligonucleotide M14 (mutated at -3 and -2 bp sites) or M15 (mutated at -2 and -1 bp sites). Oligonucleotides M11 and M16-20 (data obtained by M18-20, not shown) completely abolished the formation of the DNA-protein complexes. These results suggest that the sequence from -5 bp to -2 bp plays a critical role in binding these proteins, and that these proteins contribute to the stimulation of transcription of the human AT 1 receptor gene. Nuclear proteins binding specifically to AT 1 PRE3, however, were not detected in the extracts from 8505C cells that did not express AT 1 receptor (Fig. 8) .
Estimation of the relative contribution of each of the PREs to human AT 1 gene promoter activity
To evaluate the extent of the relative contribution of each of the PREs to the promoter activity of the human AT 1 gene, we generated reporter constructs in which inactivating mutations were introduced in various combinations into the 4 PREs, AT 1 PRE1-4, in the proximal promoter region (-150/+79 bp), and compared the promoter activities (Fig. 9) . In PLC cells, the introduction of mutations into both AT 1 PRE1 and AT 1 PRE2 (M3 + M4) reduced the luciferase activity to 23.1% of that of a wild-type construct. The introduction of mutations into AT 1 PRE4 (M7) decreased the activity to 42.5%. The introduction of M7 in addition to M3 + M4 (M3 + M4 + M7) further reduced the promoter activity of the construct with M3 + M4, but 12.1% of the activity of the wild type still remained. However, the introduction of M14 into the construct with M3 Fig. 7 . Analyses of the putative TATA box-downstream region for promoter activity by introduction of serial mutations into the region from -7 to +6 bp of the AT 1 receptor gene.
A luciferase reporter construct with the wild-type sequence from -150 to +18 bp and the constructs with sequences mutated as shown in M11 to M20 (mutated sites are underlined) were generated using the pGL3-Basic Vector and PCR. The PCR was performed using the US primer and the 26-base oligonucleotide downstream primers with sequences of M11 to M20 as described under Materials and Methods. Luciferase activities were expressed as values relative to the activity induced by phAT 1 (-150/+18)Luc, which was set at 100%. Each bar represents the mean ± SD of three independent experiments.
+ M4 + M7 (M3 + M4 + M7 + M14) almost abolished the promoter activity. Removal of the M7 mutation (M3 + M4 + M14), the M3 + M4 mutations (M7 + M14), or the mutations other than the M14 mutation (M14) from the completely inactivated promoter construct (M3 + M4 + M7 + M14) was not able to recover the inactivated promoter. These findings suggested that GC-boxes (AT 1 PRE1 and AT 1 PRE2) and AT 1 PRE4 are responsible for 86-88% of the full extent of the enhancement of human AT 1 gene promoter activity. The results also indicated that AT 1 PRE3 is essential for the expression of promoter activity, and that GC-boxes and AT 1 PRE4 contribute synergistically to the enhancement of AT 1 gene transcription promoted by AT 1 PRE3.
Discussion
In contrast to two subtypes of AT 1 receptor in rodents, there is only a single AT 1 subtype in human. The promoter regions of AT 1 genes are different between human and rodents. Therefore, the transcriptional regulation mechanism of the rat AT 1a gene may not always be applicable to that of the human AT 1 Fig. 8 . Gel mobility shift analysis of the cis-acting, positively regulating element, AT 1 PRE3 (-5 to -2 bp), in the AT 1 receptor gene promoter. The radiolabeled double-stranded oligonucleotide (-8 to +18 bp) (5'-ATTCCAGCGCCTGACAGCCAGGACCC-3') was incubated with 5 µg of nuclear extracts from PLC-PRF-5 (PLC) and 8505C cells with or without (-) a 10-, 50-, or 100-fold molar excess of unlabeled wildtype (W) or mutated (M11 to M17) competitor oligonucleotides (double-stranded) as indicated, and analyzed as described under Materials and Methods. NE (-), incubation without nuclear extract. M11 to M17 were 26-base oligonucleotides (-8 to +18 bp) in which the sequence from -7 to +3 bp was mutated as shown in Fig. 7 . The arrows indicate the DNA-protein complexes formed by specific binding to the sequence from -5 to -2 bp. gene. However, there are few reports about the basal regulatory mechanism of human AT 1 gene. One of the reasons why the mechanism of tissue-specific expression of the human AT 1 gene has not been fully elucidated is that only a few human cell lines express the AT 1 receptor at a level high enough to analyze.
In the present study, we analyzed the promoter region corresponding to the sequence from -3418 to +79 bp of the human AT 1 receptor gene using PLC-PRF-5 cells derived from human liver cell carcinoma, which express a considerably high amount of the AT 1 receptor. We identified almost all of the elements that are essential for transcriptional activation. The promoter activity of the region from -3418 to +79 bp was well correlated with the ligand binding capacity or the mRNA levels for the AT 1 receptor among cell lines derived from liver (PLC) and thyroid (8505C). This suggests that cis-acting elements and their synergistic actions revealed in the present study are sufficient to explain a basal level expression of the AT 1 gene in those cells.
The present study identified four PREs, AT 1 PRE1, AT 1 PRE2, AT 1 PRE3 and AT 1 PRE4, which function in PLC-PRF-5 cells. AT 1 PRE1 contained two GC-box consensus sequences in tandem and AT 1 PRE2 contained a GC-box-like sequence. These GC-box (like) sequences proved to be PREs responsible for an enhancer function of AT 1 PRE1 and AT 1 PRE2, since introduction of mutations within these GC-boxes reduced the promoter activity to a level similar to that observed by deletion of AT 1 PRE1 or AT 1 PRE2 (Figs. 1 and 4) . Because nuclear proteins bound to AT 1 PRE2 were all supershifted by the addition of anti-Sp1 antibody, the transcriptional factor bound to AT 1 PRE2 seemed to be Sp1. DNA-protein complexes for AT 1 PRE2 were observed as two major bands, and those for AT 1 PRE1 as four major bands by gel mobility shift analyses. Approximately 50% of nuclear proteins bound to AT 1 PRE1 were supershifted by the addition of anti-Sp1 antibody. These results suggested that transcriptional factors other than Sp1 act on AT 1 PRE1. Indeed, Zhao et al. reported that the GC-box in the proximal promoter region of the human AT 1 gene is important for high expression in a human adrenocortical carcinoma cell line, H259-R cells [33, 34] . Although they did not report the PRE corresponding to AT 1 PRE2, they found enhancer activity in the sequence from -114 to -94 bp, which is almost identical to the region of AT 1 PRE1. They suggested that Sp1, Sp3 and an unknown transcriptional factor(s) bind to that region and enhance promoter activity. Although we did not use an anti-Sp3 antibody, it is possible that a similar mechanism may function in PLC-PRF-5 cells.
DNA-protein complexes for AT 1 PRE1 or AT 1 PRE2 were detected not only in PLC-PRF-5 cells, which express the AT 1 receptor, but also in 8505C cells, which do not express the AT 1 receptor. Furthermore, it was revealed that AT 1 PRE1 and AT 1 PRE2 act as an enhancer in the human AT 1 gene promoter in both cell lines. These results suggest that AT 1 PRE1 and AT 1 PRE2 are not involved in tissue-specific expression of the human AT 1 receptor, but that they are general strong enhancers. These findings are consistent with the fact that Sp1 acts as a general transcriptional activator, which is expressed in many tissues.
We also showed here novel enhancer regions, AT 1 PRE3 and AT 1 PRE4, which are necessary for the induction of basal promoter activity of the human AT 1 gene. Nuclear proteins binding specifically to AT 1 PRE3 or AT 1 PRE4 were not detected by DNase I protection assay (not shown), but were detected in PLC-PRF-5 cells by gel mobility shift assay (Figs. 6 and 8 ). Since the changes in binding capability to nuclear proteins of AT 1 PRE3 and AT 1 PRE4 by introducing mutations within these regions were consistent with those of the promoter activity (Figs. 5-8) , it is strongly suggested that the transcriptional factors binding specifically to AT 1 PRE3 and AT 1 PRE4 regulate the promoter activity of the human AT 1 gene. Although we cannot find a consensus sequence(s) corresponding to AT 1 PRE3 and AT 1 PRE4 in transcription factor databases, the identification of transcription factors binding to these PRE regions is important for elucidation of the transcriptional regulation mechanism of the human AT 1 gene.
When inactivating mutations were introduced into all of the four PREs, the promoter activity of the AT 1 gene was almost abolished in PLC-PRF-5 cells (Fig. 9 , M3 + M4 + M7 + M14). Therefore, these four PREs are strongly suggested to play a critical role in determination of promoter activity in PLC cells. Furthermore, AT 1 PRE3 was found to be the most important element among the four PREs for expression of the AT 1 gene, because AT 1 PRE1, AT 1 PRE2 and AT 1 PRE4 could not function when AT 1 PRE3 was inactivated (see M3 + M4 + M7 + M14, M3 + M4 + M14, M7 + M14, and M14 in Fig. 9 ). The extent of enhancement of promoter activity by AT 1 PRE3 appears to be only 12 to 14% (M3 + M4 + M7, Fig.9 ) of the full enhancement, but synergistic actions of GC-boxes and AT 1 PRE4 on AT 1 PRE3 led to the full activation of the human AT 1 gene promoter (Fig. 9) .
The observation that a nuclear protein specifically bound to AT 1 PRE3 was not detected in 8505C cells (Fig. 8) , which do not express the AT 1 receptor, also suggests the importance of AT 1 PRE3 in the expression of the AT 1 gene. Several groups including Zhao et al. have characterized the basal promoter activity of the human AT 1 gene [33, 34] . Beason et al. reported that in rat vascular smooth muscle cells an A/T-rich sequence (5'-TTTAAAAATAA-3') located from -557 to -486 bp in the rat AT 1a gene promoter is important, and that MEF2 (myocyte enhancer binding factor) interacts with this A/T-rich sequence [36] . Wyse et al. reported that using a human kidney-derived cell line, LRCC8, a GAGA box (5'-GAGAGGGAGGAG-3') located from -161 to -149 bp in the human AT 1 gene promoter is necessary for basal and growth hormoneinduced transcriptional activation of the human AT 1 gene [37] . Holzmeister et al. reported that in bovine vascular smooth muscle cells, an AP-1 and a PEA3 element located from -368 to -399 bp in the human AT 1 gene promoter are involved in basal and phorbol 12-myristate 13-acetate (PMA)-induced transcriptional activation [38] . Those reported PREs could not be detected in our study, and thus the reported elements essential for basal promoter activity, including our results, are different by the type of cells used. Therefore, it is likely that the transcription factors used for the expression of the AT 1 gene are variable with different types of cells, tissue or species. Further studies in various tissues may be necessary for the elucidation of the tissue-specific transcription mechanism of the AT 1 gene.
In conclusion, we identified four cis-acting elements that are responsible for the full basal promoter activity for human AT 1 gene in liver cells. We believe that our findings will be useful in analyzing the expression mechanism of the human AT 1 gene in other tissues and cells.
